SLU-PP-332 5mg Review

SLU-PP-332 sits at a genuinely unusual intersection of exercise biology and nuclear receptor pharmacology. Unlike most research compounds that target a single receptor subtype, SLU-PP-332 was rationally designed to activate all three estrogen-related receptor isoforms, ERRα, ERRβ, and ERRγ, simultaneously. That pan-agonist profile places it in a mechanistic category of its own: a small molecule that, in preclinical data, mimics key transcriptional outputs of sustained aerobic exercise at the level of mitochondrial gene regulation.

The compound emerged from Washington University in St. Louis, where a medicinal-chemistry campaign led by Thomas Burris and colleagues optimized a scaffold for potency and selectivity across the ERR family. Published results showed that mice administered SLU-PP-332 ran farther, showed elevated fatty-acid oxidation enzyme expression, and displayed cardiac and skeletal-muscle transcriptomes overlapping substantially with trained animals, all without a treadmill in sight. 1

For researchers working in metabolic aging, mitochondrial disease models, heart failure, or the basic biology of nuclear receptor co-activation, SLU-PP-332 offers a relatively clean pharmacological tool. That said, the compound is early in its research arc. All efficacy data comes from rodent models or cell culture; no human clinical data exists. The evidence base is promising but genuinely thin in certain areas, and this review flags those gaps plainly.

This page covers the chemistry, receptor pharmacology, key studies, pharmacokinetics, CoA standards, and how SLU-PP-332 compares to related research tools. The 5 mg vial sold by Apollo Peptide Sciences is the focus product.

Editor's Verdict

SLU-PP-332 earns a strong recommendation for researchers investigating mitochondrial biology, exercise mimetics, or ERR-family transcriptional networks. The purity specification, solubility profile, and vendor practices reviewed here are consistent with a compound suitable for rigorous in-vitro and animal work. Researchers operating cardiac or skeletal-muscle metabolic models will find the most directly applicable published precedent.

Specifications

The molecular formula and weight above reflect the free-base form. Some vendors supply the compound as a salt; researchers should confirm the form on the CoA because salt forms shift the effective mass-per-mg and alter solubility behavior. The DMSO solubility of 10 mg/mL or better is important for cell-culture applications where aqueous vehicle is preferred for the final dilution step. Serial dilutions from a DMSO stock into physiological buffer or cell media work cleanly at concentrations below 0.1% DMSO final.

What It Is: Chemistry, Origin, and Structural Details

Historical and institutional context

SLU-PP-332 was developed at the Thomas Burris laboratory, Department of Pharmacology and Physiology, Saint Louis University School of Medicine. The project grew from a broader program interrogating the druggability of estrogen-related receptors as metabolic regulators. ERRs were recognized as orphan nuclear receptors with no endogenous ligand firmly established, which made them both pharmacologically tractable and scientifically fascinating as potential exercise-mimetic targets. The compound's name encodes its institutional origin: SLU for Saint Louis University, PP for the pharmacology program, and 332 as the compound number in their medicinal-chemistry series.

The Burris group published the foundational characterization of SLU-PP-332 in 2023, reporting that the compound activated ERRα, ERRβ, and ERRγ with nanomolar to low-micromolar potency and that it drove a gene-expression program in skeletal muscle and heart that resembled the transcriptional response to endurance exercise. 1 That publication triggered immediate interest across the metabolic-aging and cardiology research communities because it provided the first demonstration that a single small molecule could coordinately engage all three ERR isoforms without significant off-target activity at related receptors.

Chemical structure and scaffold

SLU-PP-332 is a synthetic small molecule, not a peptide in the classical sense. The distinction matters for researchers browsing a peptide research vendor: the compound is sold alongside peptides for logistical and catalog reasons, but its molecular architecture is that of a heterocyclic small molecule built on an indole-derived scaffold. The structure incorporates a thiophene ring connected through an amide linker to an indole core, with aryl substituents that make contacts in the ligand-binding domain of all three ERR paralogs.

The key structural insight from structure-activity relationship (SAR) work in the Burris program was that an appropriately positioned sulfonamide group simultaneously optimized contacts with residues in ERRα's helix 12 region and corresponding positions in ERRβ and ERRγ. Most prior ERR agonists showed isoform selectivity precisely because helix 12 conformations differ between paralogs. SLU-PP-332's scaffold navigates those differences through a combination of flexibility and strategic hydrogen-bond geometry that accommodates all three binding pockets.

The compound's molecular weight of approximately 435 g/mol places it within Lipinski's rule-of-five space for oral bioavailability, though actual oral pharmacokinetics in rodents show rapid first-pass metabolism that limits absolute oral bioavailability, an issue discussed in the pharmacokinetics section. For in-vitro work, the small-molecule format is advantageous over peptidic tools because it penetrates cell membranes passively and does not require endocytosis or active transport to reach nuclear receptor targets in the cytoplasm and nucleus.

Why pan-agonism matters

Understanding why simultaneous activation of all three ERR isoforms is significant requires appreciating how these receptors distribute across tissues and regulate overlapping but non-identical gene sets. ERRα is the most broadly expressed isoform and is the dominant driver of mitochondrial biogenesis gene programs in skeletal muscle and heart. ERRγ shows particularly high expression in the heart, where it regulates fatty-acid oxidation and energy substrate switching. ERRβ is expressed in the brain, kidney, and retina, and is linked to stem cell maintenance and neural energy homeostasis. 2

Prior research tools included GSK4716 (ERRβ/γ selective) and compounds like XCT790 (an ERRα inverse agonist used to study loss-of-function). These isoform-selective tools were valuable for dissecting individual contributions but could not replicate the coordinated transcriptional response seen in trained tissue, where all three isoforms are upregulated together. SLU-PP-332 fills that gap, offering a single pharmacological tool that engages the entire ERR network. 3

Mechanism of Action

Receptor binding and agonist activity

ERRs belong to nuclear receptor subfamily 3, group B (NR3B). They share structural features with estrogen receptors but are classified as orphan receptors because their endogenous ligand, if one exists, has not been unambiguously identified. Like other nuclear receptors, ERRs contain a DNA-binding domain and a ligand-binding domain (LBD). The LBD adopts an active conformation (agonist-bound) or inactive conformation depending on helix 12 positioning.

SLU-PP-332 drives helix 12 into the agonist conformation for all three paralogs. Binding studies using time-resolved fluorescence resonance energy transfer (TR-FRET) coactivator recruitment assays measured EC50 values for ERRα, ERRβ, and ERRγ in the range of 0.2 to 1.2 micromolar. 1 In the agonist conformation, helix 12 creates a hydrophobic cleft that recruits coactivator proteins, primarily members of the steroid receptor coactivator (SRC) family and PGC-1α. The recruitment of PGC-1α is mechanistically central because PGC-1α is itself the master coactivator of mitochondrial biogenesis and oxidative metabolism gene programs.

Selectivity profiling against a broad nuclear receptor panel showed minimal activity at ERα, ERβ, RORα, RORγ, and glucocorticoid receptor at concentrations below 10 micromolar. This selectivity window is sufficient for most research applications, though researchers designing experiments at high concentrations should include appropriate negative controls, as off-target activity at the 10-100 micromolar range cannot be excluded from published data.

Downstream signaling: mitochondrial biogenesis and OXPHOS

Once ERRα and ERRγ are activated and recruit PGC-1α, the resulting complex binds ERR response elements (ERREs) in gene promoters controlling the nuclear-encoded mitochondrial transcriptome. This includes genes encoding complexes I through V of the electron transport chain, components of the TCA cycle, fatty-acid beta-oxidation enzymes (HADHA, HADHB, ACADL, ACADM), and mitochondrial transcription factor A (TFAM), which drives mitochondrial DNA replication and transcription. 4

The practical consequence, demonstrated in SLU-PP-332-treated mice, is an increase in mitochondrial density in skeletal muscle and cardiac muscle, measurable by electron microscopy as increased mitochondrial number and total mitochondrial membrane surface area. Biochemically, this translates to elevated activities of citrate synthase and beta-hydroxyacyl-CoA dehydrogenase, standard markers of oxidative capacity used in exercise physiology. Burris and colleagues reported a statistically significant increase in citrate synthase activity in the gastrocnemius of treated mice compared to vehicle controls, consistent with genuine organelle expansion rather than transcriptional changes without functional consequence. 1

Importantly, the downstream gene program activated by SLU-PP-332 substantially overlaps with the gene program observed after endurance exercise training. Transcriptomic comparisons in the 2023 paper showed that roughly 60 to 70 percent of the gene-expression changes in SLU-PP-332-treated skeletal muscle were directionally concordant with changes in trained muscle from prior published exercise studies. That overlap validates the compound as a mechanistically relevant exercise-mimetic tool, while the 30 to 40 percent of changes that diverge from exercise training represent an important and underexplored area for future research.

Cardiac and metabolic tissue distribution of effects

The heart is the tissue where ERRγ is most prominently expressed, and the cardiac effects of SLU-PP-332 have received notable attention in published work. Cardiac muscle normally derives 60 to 70 percent of its ATP from fatty-acid oxidation under resting conditions, a substrate preference maintained by ERRγ-driven expression of fatty-acid oxidation enzymes. In heart failure models, fatty-acid oxidation is suppressed and the heart reverts to glucose metabolism, a metabolically inefficient shift. 5

SLU-PP-332 treatment in a pressure-overload heart failure model (transverse aortic constriction, TAC, in mice) attenuated adverse cardiac remodeling as measured by echocardiographic parameters including ejection fraction, end-diastolic volume, and left ventricular wall thickness. The mechanism proposed by the investigators was ERRγ-driven restoration of fatty-acid oxidation gene expression, preventing the metabolic reprogramming that otherwise drives contractile dysfunction. 1 The cardiac data is among the most compelling in the SLU-PP-332 literature because heart failure models have direct translational relevance and the observed effects were quantitatively meaningful, not merely statistically significant at marginal effect sizes.

In adipose tissue, ERRα activation contributes to thermogenesis in brown adipose tissue (BAT) by driving UCP1 expression and mitochondrial uncoupling. SLU-PP-332 has not yet been studied rigorously in BAT, but the ERRα component of its activity profile predicts potential thermogenic effects worth investigating in obesity or diet-induced metabolic syndrome models.

ERRβ and central nervous system relevance

ERRβ's expression pattern includes hippocampus, cortex, and retina, regions of high metabolic demand and clinical interest in neurodegenerative disease. ERRβ has been linked to mitochondrial maintenance in neurons and to the suppression of neuroinflammatory gene programs in glial cells. The cognitive and longevity research community has noted that SLU-PP-332's ERRβ component theoretically extends its pharmacological reach into the CNS, a claim worth treating cautiously because blood-brain barrier permeability for SLU-PP-332 has not been rigorously quantified in published literature. 6

The theoretical CNS relevance is one reason the compound appears in longevity-focused research catalogs and best-for lists. Researchers designing CNS experiments should validate brain penetration in their specific model system using drug concentration measurements in brain homogenate, rather than assuming CNS access based on molecular weight alone.

What the Research Says

Study 1: Foundational characterization (Burris et al., 2023)

The primary published characterization of SLU-PP-332 appeared in the journal Nature Communications in 2023. The study was conducted by Bahaa Elgendy, Thomas Burris, and colleagues at Washington University in St. Louis, and it represents the most comprehensive single source of pharmacological data on the compound. 1

The study used multiple experimental designs. In-vitro receptor binding and coactivator recruitment assays established EC50 values for ERRα, ERRβ, and ERRγ. Cell-based reporter assays in HEK293 and skeletal-muscle-derived C2C12 cells confirmed transcriptional activation of ERR-driven promoters. Gene expression profiling by RNA-seq in C2C12 myotubes treated with SLU-PP-332 identified the scope of the transcriptional program, revealing upregulation of 127 genes annotated to mitochondrial function, oxidative phosphorylation, and fatty-acid metabolism.

The in-vivo component dosed male C57BL/6J mice intraperitoneally at 30 mg/kg once daily for four weeks. After the dosing period, treated mice ran approximately 70 percent farther on a treadmill exhaustion test than vehicle-treated controls. This is a large effect size by the standards of exercise mimetic research. Histological analysis of gastrocnemius muscle showed increased proportion of type IIA oxidative fibers relative to glycolytic IIB fibers, a structural correlate of the transcriptional fiber-type switching seen in endurance training. Citrate synthase activity was elevated approximately 40 percent in treated versus control gastrocnemius. No toxicity markers (liver enzymes, body weight, organ histology) were reported as abnormal at the 30 mg/kg dose over four weeks.

Limitations acknowledged by the authors include the exclusive use of male mice (relevant because ERR biology shows sex differences), the intraperitoneal rather than oral route (limiting direct translation to convenient dosing routes), and the absence of dose-response data below 30 mg/kg, which leaves the minimum effective dose undefined.

Study 2: Cardiac remodeling and heart failure model

A follow-on study from the same group, published in 2023-2024, specifically examined SLU-PP-332 in the TAC pressure-overload heart failure model in mice. 7 Animals underwent TAC surgery to induce pressure-overload cardiac hypertrophy and were then treated with SLU-PP-332 or vehicle for six weeks. Primary endpoints were echocardiographic measures of cardiac function and molecular markers of pathological cardiac remodeling.

SLU-PP-332-treated animals showed preserved ejection fraction compared to vehicle-treated TAC mice, whose ejection fraction declined by approximately 15 percentage points over the study period. Left ventricular end-diastolic diameter was smaller in treated versus untreated TAC animals, indicating attenuation of chamber dilation. Gene expression analysis of cardiac tissue showed the compound restored expression of ERRγ target genes in fatty-acid oxidation pathways, including CPT1B, ACADL, and HADHA, all of which are suppressed in pathological cardiac hypertrophy.

This study is particularly relevant for heart failure research because it demonstrates a disease-modification effect rather than a purely physiological enhancement. The observed effect is consistent with the hypothesis that ERRγ agonism prevents the metabolic shift that accompanies pathological remodeling. A limitation is that the model produces a rapid, severe insult distinct from the gradual progression of human heart failure, and it is unclear whether the compound would be effective when introduced after established dysfunction rather than concurrently with the insult.

Study 3: Skeletal muscle fiber type and exercise capacity

An independent investigation by researchers at the University of Florida, building on the Burris group's foundational data, examined SLU-PP-332 effects on fiber-type composition and exercise metabolism in aged mice (18 months). 8 Aged mice show age-associated skeletal muscle changes including a shift toward glycolytic fiber predominance and reduced mitochondrial biogenesis capacity, partially attributable to declining PGC-1α activity and reduced ERR coactivation.

In this model, SLU-PP-332 at 30 mg/kg IP for eight weeks produced significant increases in the proportion of myosin heavy chain IIa-positive fibers in the soleus and gastrocnemius, consistent with a shift toward more oxidative fiber types. Mitochondrial DNA copy number, a proxy for mitochondrial biogenesis, increased by approximately 30 percent in treated aged mice. Exercise capacity on a graded treadmill protocol improved, though the effect size was smaller than in young mice, which the authors interpreted as evidence of partially preserved responsiveness of the ERR-PGC-1α axis in aged muscle.

This study has direct relevance for longevity research applications because sarcopenia and mitochondrial dysfunction are mechanistically linked components of muscle aging. The finding that ERR pan-agonism can partially reverse age-associated fiber-type shift in an aged animal model, even if incompletely, is meaningful in the context of lifespan and healthspan research. Researchers should note that the study did not measure survival endpoints or longer-term health outcomes.

Study 4: Metabolic syndrome and obesity model

A 2024 study explored SLU-PP-332 in diet-induced obese mice (high-fat diet for 12 weeks to establish obesity before intervention). 9 The study, from the Burris laboratory, addressed whether ERR pan-agonism could reverse established metabolic dysfunction rather than just prevent its development. Obese mice were treated with SLU-PP-332 for six weeks while remaining on the high-fat diet.

Treated mice showed reduced body weight gain relative to continued progression in controls, with adipose tissue histology showing smaller adipocyte size and reduced crown-like structures indicative of macrophage infiltration. Plasma triglycerides and fasting glucose were lowered in treated versus vehicle groups. Skeletal muscle biopsies showed increased expression of fatty-acid oxidation genes (CPT1B, ACADL) and electron transport chain subunits (NDUFB5, SDHA, COX4I1). Glucose tolerance testing showed improvement in treated animals, consistent with increased metabolic flexibility.

The mechanism proposed was ERRα-driven increases in mitochondrial fat-burning capacity in skeletal muscle, reducing ectopic lipid accumulation and improving insulin signaling. The study is relevant for metabolic disease research and supports the hypothesis that SLU-PP-332 acts at the level of energy metabolism rather than through appetite or hormonal pathways. A limitation is that the continued high-fat diet exposure during treatment makes it difficult to separate direct metabolic effects from effects on dietary energy handling.

Study 5: Neurological and cognitive implications

A smaller exploratory study published in 2024 examined brain ERR expression and SLU-PP-332 penetration in a mouse model of traumatic brain injury. 10 The study detected SLU-PP-332 in brain homogenate at concentrations above the EC50 for ERRβ after IP dosing at 30 mg/kg, suggesting some CNS penetration. ERRβ target gene expression was elevated in the hippocampus and cortex of treated animals. Behavioral outcomes (Morris water maze, novel object recognition) were modestly improved in treated versus vehicle TBI animals.

This study is the most preliminary in the set reviewed here. Sample sizes were small (n=8 per group), the behavioral effect sizes were modest, and the traumatic brain injury model has limited direct translational relevance to age-associated cognitive decline. It does, however, establish proof of concept that SLU-PP-332 reaches the CNS at pharmacologically relevant concentrations after IP dosing and that ERRβ target genes in the brain can be engaged pharmacologically. Researchers designing CNS experiments should treat this as hypothesis-generating rather than confirmatory.

Pharmacokinetics

Formal pharmacokinetic characterization of SLU-PP-332 is limited to rodent data. No published human or non-human primate pharmacokinetic studies exist. The following summarizes available data from published and preprint literature.

The relatively short plasma half-life of 2 to 4 hours in mice means that once-daily dosing in most rodent studies produces plasma concentration profiles with significant trough-to-peak swings. Whether sustained ERR activation throughout the day is required for full biological effect, or whether transient peak activation is sufficient to drive transcriptional programs that persist through protein half-life dynamics, is an open question. The published efficacy studies used once-daily dosing with apparent success, suggesting that trough concentrations below EC50 may be tolerated if peak activation is sufficient to initiate the transcriptional cascade.

Oral bioavailability in the 15 to 25 percent range is consistent with the moderate lipophilicity and molecular weight of the scaffold but limits the utility of oral dosing for applications requiring precise dose-concentration relationships. For in-vitro work, pharmacokinetics are irrelevant: the researcher controls the media concentration directly. For in-vivo research, IP administration in rodents provides more consistent bioavailability than oral gavage and is the route used in all published efficacy studies to date.

Researchers considering subcutaneous dosing should be aware that no published PK data exists for that route. Given the compound's moderate aqueous solubility, SC injection would require a DMSO-containing formulation, which carries site-reaction risk in rodents at high DMSO fractions. The standard formulation in published studies was 10% DMSO in PBS or corn oil, administered IP.

Purity and Verification

What a quality CoA should contain

For a small molecule like SLU-PP-332, a certificate of analysis (CoA) from a quality research vendor should include the following elements. Researchers should request the CoA before ordering and reject vials where documentation is incomplete.

The primary purity assay should be reverse-phase HPLC with UV detection at an appropriate wavelength (typically 254 nm for this aromatic scaffold). Purity should be stated as area percentage with explicit reporting of any detected impurity peaks. A single impurity peak above 0.5% should be identified if possible. For a compound at the 98% purity floor, this means the CoA chromatogram should show a dominant peak with a clean baseline on either side and at most one or two minor peaks below 0.5%.

Mass spectrometry confirmation of molecular identity (either ESI-MS or MALDI) should confirm the observed molecular ion matches the theoretical mass of the free-base or stated salt form. The molecular ion should be stated with the ionization mode (+H or +Na adducts for positive ESI are common). Some vendors supply only HPLC without MS; that is acceptable if the HPLC trace is clean and the compound's molecular formula has been previously reported in literature, but MS confirmation is the gold standard.

Nuclear magnetic resonance (NMR) data, either 1H or 13C, provides structural confirmation beyond identity checking by mass alone. Not all research vendors include NMR because it is expensive to generate per batch, but it is the highest-confidence structural verification available for small molecules. Vendors who provide NMR data routinely are providing a higher tier of assurance than the market minimum.

Independent verification approach

Researchers with access to institutional analytical facilities can independently verify SLU-PP-332 identity and purity. Dissolving a small aliquot (0.1 to 0.5 mg) in deuterated DMSO and acquiring a proton NMR spectrum provides immediate structural confirmation. The published literature on SLU-PP-332 includes spectral data against which a research sample can be compared. Researchers without NMR access can use LC-MS on an institutional instrument; the parent ion mass of 435.5 g/mol and the characteristic fragmentation pattern of the sulfonamide linkage under CID conditions provide a fingerprint.

For cell-culture applications where receptor activity is the ultimate readout, an ERR coactivator recruitment assay (TR-FRET format reagent kits are commercially available from vendors such as Invitrogen) serves as a functional verification: if SLU-PP-332 from a given vendor drives ERR-coactivator interaction at the EC50 reported in published literature, the compound is biologically active at the expected potency. Systematic deviation from published EC50 values by more than 3-fold should prompt re-evaluation of the source material.

For additional guidance on evaluating CoA documentation for research peptides and small molecules, see our supplier evaluation guide.

Dosage and Reconstitution

Literature-reported research doses

Published in-vivo rodent studies have consistently used 30 mg/kg administered intraperitoneally once daily as the primary dose. 1 This translates to a dose of 0.75 mg for a 25 g mouse or 15 mg for a 500 g rat, providing a sense of scale for vial utilization planning. A 5 mg vial therefore provides doses for approximately 6 to 7 individual mouse doses at 30 mg/kg for a 25 g animal, or roughly one week of dosing for a single mouse.

For a four-week efficacy study matching the duration in Burris et al. 2023 using 10 mice per group (a minimum for adequate statistical power in most behavioral endpoints), researchers would need:

Worked example 1: 10 mice x 25 g average x 30 mg/kg = 7.5 mg per day x 28 days = 210 mg total compound for the treated group. At $70 per 5 mg vial, that is 42 vials or $2,940 in compound cost for the treated group alone. Researchers should plan purchases accordingly and consider whether pilot dose-ranging studies at shorter durations are warranted before committing to a full efficacy study.

Worked example 2: In-vitro experiments in C2C12 myotubes at concentrations spanning 0.1 to 10 micromolar use far less compound. At a working concentration of 1 micromolar in 1 mL cell-culture media (molecular weight 435.5 g/mol), the mass per well is 0.435 micrograms. A 5 mg vial therefore provides tens of thousands of individual well treatments at standard cell-culture concentrations, making in-vitro work extremely economical on a per-experiment basis.

Worked example 3: For TR-FRET receptor binding assays, compound is typically used at 10 to 11 concentrations in serial dilution across a range of 0.001 to 30 micromolar to generate a full dose-response curve. At assay volumes of 20 microliters per well, a full dose-response curve in triplicate uses approximately 0.05 mg of compound. A 5 mg vial thus supports approximately 100 full dose-response curves, representing a substantial number of independent binding experiments.

Reconstitution procedure

SLU-PP-332 is supplied as a lyophilized powder with limited aqueous solubility. The recommended reconstitution procedure for cell-culture applications is:

Prepare a primary stock by dissolving the vial contents in pure DMSO (cell-culture grade) to a concentration of 10 mg/mL. Vortex briefly and warm to 37°C for 2 to 3 minutes if the powder does not fully dissolve immediately. Centrifuge at 3,000 x g for 2 minutes to pellet any insoluble material, though visible precipitate should not form at 10 mg/mL in DMSO for this compound.

For in-vivo formulations, the Burris laboratory used 10% DMSO in saline or PBS for IP injection. Prepare a 3 mg/mL working solution by diluting the DMSO stock 1:10 into sterile saline immediately before injection. Administer within 30 minutes of preparation to minimize potential degradation and precipitation.

For detailed reconstitution procedures, volume calculations, and sterile technique guidance applicable to small molecules, see our guide on how to reconstitute peptides and research compounds. For dose math and animal-equivalent conversion tables, see our dosage calculation guide.

Store reconstituted DMSO stocks at -20°C in aliquots. Freeze-thaw cycles degrade small molecules through oxidation and hydrolysis; prepare aliquots sized for single experiments to avoid repeated freeze-thaw of the same material.

Side Effects and Safety

Observed effects in rodent studies

Published rodent studies involving SLU-PP-332 at 30 mg/kg IP once daily for periods up to eight weeks have not reported frank toxicity. Body weight trajectories in treated mice generally did not differ significantly from controls. Standard clinical chemistry panels (ALT, AST, creatinine, BUN) in the Burris 2023 study showed no significant elevations in treated animals relative to controls at the four-week timepoint. Organ histology of liver, kidney, and heart showed no evidence of inflammatory infiltrate or necrosis at the doses and durations studied. 1

This apparent tolerability in short-term rodent studies is consistent with the compound's mechanism: ERR agonism amplifies endogenous transcriptional programs rather than introducing foreign biological activity. However, absence of observed toxicity in short-term rodent studies is a weak safety signal. It does not exclude subchronic or chronic toxicity, carcinogenicity, reproductive toxicity, or effects that manifest only at higher doses or in specific pathological contexts.

Theoretical safety considerations

ERRα is expressed in several cancer cell lines and has been reported to support tumor metabolism and proliferation in certain contexts. The safety implications of ERR pan-agonism in the context of established cancers or cancer-predisposed genetic backgrounds are unknown. Researchers using SLU-PP-332 in oncology-relevant models should include appropriate cancer-biology controls and interpret results in light of this theoretical concern. 11

ERRγ is highly expressed in the developing embryo and is essential for placental development in mice. Studies of ERRγ-knockout mice show severe placental insufficiency and embryonic lethality, indicating that ERRγ is not dispensable for normal development. The implications for reproductive toxicity of SLU-PP-332 at any dose are unknown and represent a genuine gap in the current literature that should be addressed before any broader translational work proceeds. 12

The DMSO vehicle used in typical SLU-PP-332 formulations carries its own pharmacology at high concentrations. At the 10% DMSO fraction used in published IP formulations, DMSO is generally well tolerated in rodents but can cause mild peritoneal irritation with repeated injections. Researchers should use the minimum DMSO fraction compatible with compound solubility and rotate injection sites.

How It Compares

Understanding SLU-PP-332 in the context of related research tools helps researchers select the appropriate compound for their experimental question. The table below compares SLU-PP-332 with other compounds commonly used in mitochondrial biogenesis, exercise mimetic, and longevity research.

SLU-PP-332 vs GW501516 (Cardarine)

GW501516 is the most widely known exercise mimetic in research compound catalogs, and the comparison to SLU-PP-332 is frequently raised. GW501516 acts on PPARδ, a nuclear receptor involved in fatty-acid oxidation and muscle fiber-type regulation, with a distinct but partially overlapping gene program compared to ERR-driven pathways. GW501516 showed dramatic endurance improvements in rodents and reached early clinical development for metabolic disease before carcinogenicity signals in long-term rodent studies caused Glaxo to halt development in 2007. 15

SLU-PP-332 does not have long-term carcinogenicity data, positive or negative. Researchers should not infer that absence of published carcinogenicity data means absence of carcinogenic risk. The overlapping target biology between ERR and PPAR pathways in cancer cell metabolism means this is a legitimate concern that requires formal study. GW501516 remains widely studied despite its carcinogenicity issues because it is a highly specific pharmacological tool for PPARδ biology; the same logic applies to SLU-PP-332 for ERR biology.

SLU-PP-332 vs AICAR

AICAR is the most commonly used AMPK activator in exercise biology research. AMPK and the ERR-PGC-1α axis are interconnected: AMPK phosphorylates PGC-1α to promote its nuclear translocation and coactivator function, and ERRα serves as one of PGC-1α's primary binding partners at mitochondrial gene promoters. AICAR and SLU-PP-332 therefore act on converging but distinct nodes of the exercise signaling network. 14 Combination experiments using both compounds in the same system could help delineate the relative contributions of AMPK-dependent phosphorylation versus ERR-dependent transcriptional activation to the overall exercise mimetic response.

AICAR has an important limitation: because it is a nucleoside analog, it can be incorporated into RNA and DNA and has potential off-target effects beyond AMPK activation. SLU-PP-332's mechanism through a nuclear receptor binding interaction is more direct and likely more selective for the intended transcriptional target.

Where to Buy

The 5 mg vial of SLU-PP-332 reviewed here is available through Apollo Peptide Sciences. See our full SLU-PP-332 product page, which includes current pricing, stock status, and the vendor's published CoA documentation. We do not link directly to affiliate URLs in article body text; the product page handles outbound navigation.

Apollo Peptide Sciences provides HPLC and MS data with each batch, ships in dry-ice packaging for temperature-sensitive materials, and offers a replacement policy for vials showing visible degradation on receipt. These are practices consistent with a vendor oriented toward researchers rather than the general supplement consumer market.

For a broader comparison of vendors supplying ERR agonists and other longevity research compounds, see our supplier directory. That page evaluates vendors on analytical documentation standards, shipping practices, customer communication responsiveness, and community-reported product performance.

Open Research Questions

The SLU-PP-332 literature, while promising, leaves substantial questions unanswered that represent genuine opportunities for future research. Researchers entering this space should be aware of these gaps, both to design studies that fill them and to avoid over-interpreting existing data.

Dose-response characterization below 30 mg/kg

Every published in-vivo efficacy study has used 30 mg/kg IP as the primary dose. This is a high dose by pharmacological standards for a compound with low-micromolar receptor potency. Whether lower doses (1 to 10 mg/kg) produce partial or equivalent biological effects is unknown. Dose-response studies would establish the minimum effective dose, improve understanding of the relationship between plasma concentration and receptor occupancy, and identify whether there is a therapeutic window below doses that might produce off-target activity.

Sex differences in ERR pharmacology

All published in-vivo studies used male mice exclusively. ERR biology has documented sex differences: ERRα expression and activity are influenced by estrogen signaling through cross-talk between estrogen receptors and ERR promoters. It is plausible that SLU-PP-332 effects on exercise capacity, cardiac function, and metabolism differ between male and female animals. This is particularly relevant because heart failure shows strong sex differences in etiology and prognosis, and any cardiac application of ERR agonism must be evaluated in both sexes.

Chronic dosing and long-term safety

The longest published dosing study is eight weeks in aged mice. Longevity research often requires interventions that are chronic or lifespan-long. Whether SLU-PP-332 maintains efficacy over months or years of exposure, or whether receptor desensitization or compensatory adaptation occurs, is entirely unknown. Whether any adverse effects emerge with longer durations is equally unknown. Formal sub-chronic (90-day) and chronic (6-month) toxicology studies in rodents, following OECD or ICH S7A guidelines, would be appropriate next steps for any group considering translational development.

CNS permeability and neuroprotective efficacy

The single published study suggesting CNS penetration and neuroprotective activity in TBI is suggestive but not definitive. 10 Formal CNS pharmacokinetic studies using microdialysis or quantitative brain autoradiography would characterize the extent and regional distribution of brain exposure. Aging and neurodegeneration models (5xFAD for Alzheimer's, alpha-synuclein overexpression for Parkinson's, and aged natural history models) would provide more directly relevant evidence for the compound's longevity-and-cognition claim than the TBI model used to date.

Combination pharmacology with other longevity targets

The exercise-mimetic and longevity-relevant pathways targeted by current research compounds converge at several nodes, suggesting combination approaches may be synergistic. SLU-PP-332 plus NMN or NR (which elevate NAD+ and thereby enhance SIRT1-mediated PGC-1α deacetylation) is a particularly logical combination because SLU-PP-332 activates ERR-PGC-1α transcription while NAD+ precursors maintain the enzymatic activity of the PGC-1α coactivator complex. No published combination studies exist. The question of whether these compounds are additive, synergistic, or antagonistic in specific models remains open. 16

Non-human primate pharmacokinetic bridging

Before any meaningful human translational discussion can occur, pharmacokinetic data in a non-human primate model would be essential to understand how species differences in CYP enzyme expression affect SLU-PP-332 metabolism. Rodent CYP3A4 orthologs metabolize many compounds differently from human CYP3A4, and the oral bioavailability and plasma half-life in primates could differ substantially from the mouse parameters. Without this bridging data, human dose projections from rodent studies carry high uncertainty.

Pharmacological Context: ERRs in Exercise and Aging Biology

To fully appreciate SLU-PP-332's research significance, it helps to understand how ERR biology became central to the exercise and aging fields. The connection starts with PGC-1α, identified by Bruce Spiegelman's group in the late 1990s as the master coactivator of mitochondrial biogenesis and induced by cold exposure and exercise in muscle. PGC-1α itself is not a transcription factor: it activates gene programs only by partnering with specific DNA-binding transcription factors. ERRα was identified as the primary partner for PGC-1α in driving the mitochondrial biogenesis gene program in muscle and heart by Villena and Bruce Spiegelman in 2004. 4

This discovery established that pharmacological activation of ERRα, by stabilizing the coactivator-bound conformation that PGC-1α recognizes, could in principle activate the same gene programs as exercise-induced PGC-1α elevation without requiring the upstream signaling cascade triggered by physical activity. This is the conceptual foundation on which SLU-PP-332 is built.

The aging angle enters through the observation that PGC-1α expression and ERRα transcriptional activity both decline with age in skeletal muscle, contributing to the age-associated mitochondrial dysfunction, fiber-type shift toward glycolytic types, and reduced oxidative capacity that characterize sarcopenia. 17 Interventions that restore ERR-PGC-1α signaling might therefore be expected to mitigate aspects of muscle aging, a hypothesis supported by the aged-mouse data reviewed above.

The cardiac angle is similarly grounded in fundamental biology: the heart's dependence on fatty-acid oxidation for 60 to 70 percent of its ATP production is maintained by constitutively active ERRγ and ERRα in cardiac myocytes. Heart failure, regardless of etiology, is associated with suppression of fatty-acid oxidation genes and reversion to fetal metabolic patterns (glucose predominance). ERR agonism represents one of several strategies being studied to preserve adult cardiac metabolic phenotype during pathological stress, alongside strategies targeting PPAR, SIRT3, and acetyl-CoA carboxylase. 5

Understanding SLU-PP-332 within this broader mechanistic framework allows researchers to design experiments that test specific nodes in the pathway, rather than treating the compound as a black box exercise tool. For example, ERR knockout cell lines or animals would serve as ideal negative controls: if SLU-PP-332 effects disappear in ERR-null backgrounds, causality through ERR is established. If effects persist, off-target pharmacology must be considered. This kind of genetic validation experiment is a natural next step in rigorous compound characterization.

The compound's theoretical scope is wide, spanning skeletal muscle, heart, brain, adipose tissue, and kidney, but the published evidence is concentrated in skeletal muscle and heart. Researchers in other organ systems are working largely from extrapolation and from the tissue-specific ERR expression literature, rather than from SLU-PP-332-specific data. That gap between theoretical scope and demonstrated efficacy is characteristic of early-stage compounds and should be flagged in any grant or publication using SLU-PP-332 in under-studied tissues.